However, despite anti‐Aβ therapies typically having a better treatment response in APOE ε4 carriers,39 subgroup analyses in the GRADUATE studies showed that APOE ε4 carrier status, a genetic risk factor for AD,40 did not influence treatment responses. The gene discussed is APOE; the disease is Alzheimer disease.